Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease - PubMed (original) (raw)

Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease

W Kirch et al. Clin Pharmacokinet. 1987 Aug.

Abstract

The pharmacokinetics of bisoprolol were investigated following oral administration of 10mg once daily for 7 days in 8 healthy subjects, in 14 patients with different degrees of renal impairment and in 18 patients with liver disease. In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed. 5.21 mg/24 hours of unchanged bisoprolol were recovered following urinary excretion during the dosage interval. In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively. Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h. In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours. In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h. The present study indicates that in patients with impairment of kidney or liver function accumulation of bisoprolol above a factor of 2 did not occur. However, in the terminal stages of insufficiency of kidney or liver function bisoprolol dosage should not exceed 10mg.

PubMed Disclaimer

Similar articles

• Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.
  Leopold G, Pabst J, Ungethüm W, Bühring KU. Leopold G, et al. J Clin Pharmacol. 1986 Nov-Dec;26(8):616-21. doi: 10.1002/j.1552-4604.1986.tb02959.x. J Clin Pharmacol. 1986. PMID: 2878941
• The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
  Payton CD, Fox JG, Pauleau NF, Boulton-Jones JM, Ioannides C, Johnston A, Thomas P. Payton CD, et al. Eur Heart J. 1987 Dec;8 Suppl M:15-22. doi: 10.1093/eurheartj/8.suppl_m.15. Eur Heart J. 1987. PMID: 2897297
• Interaction of bisoprolol with cimetidine and rifampicin.
  Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE. Kirch W, et al. Eur J Clin Pharmacol. 1986;31(1):59-62. doi: 10.1007/BF00870987. Eur J Clin Pharmacol. 1986. PMID: 2877885
• Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
  Johnsson G, Regàrdh CG. Johnsson G, et al. Clin Pharmacokinet. 1976;1(4):233-63. doi: 10.2165/00003088-197601040-00001. Clin Pharmacokinet. 1976. PMID: 13958 Review.
• Consequences of renal insufficiency on the hepatic clearance of some drugs.
  Balant LP, Dayer P, Fabre J. Balant LP, et al. Int J Clin Pharmacol Res. 1983;3(6):459-74. Int J Clin Pharmacol Res. 1983. PMID: 6147317 Review.

Cited by

• Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac Kv4.3 (Ito) Channel Isoforms.
  Rahm AK, Hackbarth J, Müller ME, Pfeiffer J, Gampp H, Petersenn F, Rivinius R, Frey N, Lugenbiel P, Thomas D. Rahm AK, et al. Int J Mol Sci. 2023 Sep 8;24(18):13842. doi: 10.3390/ijms241813842. Int J Mol Sci. 2023. PMID: 37762145 Free PMC article.
• Pharmacokinetics of newer drugs in patients with renal impairment (Part II).
  Singlas E, Fillastre JP. Singlas E, et al. Clin Pharmacokinet. 1991 May;20(5):389-410. doi: 10.2165/00003088-199120050-00004. Clin Pharmacokinet. 1991. PMID: 1879096 Review.
• Population pharmacokinetic analysis of bisoprolol.
  Grevel J, Thomas P, Whiting B. Grevel J, et al. Clin Pharmacokinet. 1989 Jul;17(1):53-63. doi: 10.2165/00003088-198917010-00005. Clin Pharmacokinet. 1989. PMID: 2568209 Clinical Trial.
• Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).
  Ogawa R, Stachnik JM, Echizen H. Ogawa R, et al. Clin Pharmacokinet. 2014 Dec;53(12):1083-114. doi: 10.1007/s40262-014-0189-3. Clin Pharmacokinet. 2014. PMID: 25248847 Review.
• In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressures.
  Jansson SO, Malm AE, Lundström T. Jansson SO, et al. Drugs R D. 2014 Dec;14(4):325-32. doi: 10.1007/s40268-014-0073-5. Drugs R D. 2014. PMID: 25488798 Free PMC article.

References

1. 1. Eur J Clin Pharmacol. 1986;31(1):59-62 - PubMed
2. 1. J Clin Pharmacol. 1983 Apr;23(4):171-7 - PubMed
3. 1. Clin Pharmacokinet. 1980 Mar-Apr;5(2):169-80 - PubMed
4. 1. Cardiology. 1979;64 Suppl 1:1-13 - PubMed
5. 1. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):591-7 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information